Session: 321. Coagulation and Fibrinolysis: Basic and Translational: Poster III
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Bleeding and Clotting, hemophilia, Diseases
Aims: To identify factor combinations that enhance or attenuate thrombin generation in mild, moderate, and severe hemophilia A, B, and C.
Methods: Plasma levels for factors II, V, VII, VIII, IX, X, XI, tissue factor pathway inhibitor (TFPI), and antithrombin (AT) were fixed at one of three values: 50%, 100%, or 150% of normal. We simulated all possible combinations of these three factor levels for normal blood, and mild, moderate, and severe hemophilia A, B, and C type blood, characterized by deficiencies of 10, 5, and 1% of normal plasma levels. For each combination of factor levels, tissue factor (TF) was varied, and combinations of factor levels were identified as thrombin enhancing (or attenuating) when they resulted in at least a 10-fold increase (or decrease) in detectable thrombin levels. We used an updated version of our mathematical model that includes interactions between TFPI and partially cleaved FV.
Results: For simulations of severe hemophilia A and B, combinations of low normal levels (50%) of FV and TFPI and high normal levels (150%) of FII and FX lead to an increase in total thrombin. Interestingly, the opposite combinations (high normal FV and TFPI, low normal FII and FX) led to a decrease in total thrombin for simulations of mild hemophilia A and B. In some of the severe deficiency cases, high normal FVIII levels in hemophilia B and low normal FIX levels in hemophilia A were found to enhance thrombin generation. In normal blood and hemophilia C, combinations of low normal levels (50%) of FV and TFPI and high normal levels (150%) of FVIII and FIX led to an increase in total thrombin, and again the opposite levels attenuated thrombin generation. In some cases, low normal levels of AT also enhanced thrombin generation.
Conclusion(s): Our mathematical model identified new and testable combinations of parameters that enhance thrombin generation in severe hemophilia and attenuated thrombin generation in mild hemophilia.
Disclosures: Monroe: Sanofi: Research Funding. Leiderman: Novo Nordisk: Research Funding.
See more of: Oral and Poster Abstracts